title: Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study.
abstract: The potential effects of Cerebrolysin (EBEWE Pharma, Unterach, Austria), a peptide preparation with neurotrophic activity, on brain bioelectrical activity, cognitive performance and clinical outcome in postacute traumatic brain injury (TBI) patients, were investigated in an exploratory study. A decrease in slow electroencephalogram (EEG) activity and an increase in fast frequencies were observed after the administration of Cerebrolysin. This EEG-activating effect was not influenced by TBI time course or severity, nor by the chronic treatment with nootropic compounds. Cognitive performance, evaluated with the Syndrome Kurztest test, improved in TBI patients after Cerebrolysin treatment, independent of disease severity, time course or disability. A significant improvement in the patients' clinical outcome, only evident during the first year after brain trauma, was also found following Cerebrolysin infusions. No relevant changes in biological parameters nor drug-related adverse events were observed. These promising preliminary results suggest that Cerebrolysin might be a useful treatment to improve the recovery of patients with traumatic brain damage, and encourage the conduction of confirmatory clinical trials.
authors.affiliation: EuroEspes Biomedical Research Center, Santa Marta de Babia, 15166-Bergondo, A Coruña, Spain. me-direccion@euroespes.com
authors.forename: X Antón
authors.initials: XA
authors.lastname: Alvarez
authors.forename: Carolina
authors.initials: C
authors.lastname: Sampedro
authors.forename: Paula
authors.initials: P
authors.lastname: Pérez
authors.forename: Marta
authors.initials: M
authors.lastname: Laredo
authors.forename: Verónica
authors.initials: V
authors.lastname: Couceiro
authors.forename: Angeles
authors.initials: A
authors.lastname: Hernández
authors.forename: Jesús
authors.initials: J
authors.lastname: Figueroa
authors.forename: Miguel
authors.initials: M
authors.lastname: Varela
authors.forename: Dulce
authors.initials: D
authors.lastname: Arias
authors.forename: Lola
authors.initials: L
authors.lastname: Corzo
authors.forename: Raquel
authors.initials: R
authors.lastname: Zas
authors.forename: Valter
authors.initials: V
authors.lastname: Lombardi
authors.forename: Lucía
authors.initials: L
authors.lastname: Fernández-Novoa
authors.forename: Victor
authors.initials: V
authors.lastname: Pichel
authors.forename: Ramón
authors.initials: R
authors.lastname: Cacabelos
authors.forename: Manfred
authors.initials: M
authors.lastname: Windisch
authors.forename: Manuel
authors.initials: M
authors.lastname: Aleixandre
authors.forename: Herbert
authors.initials: H
authors.lastname: Moessler
mesh_terms: D000293:Adolescent; D000328:Adult; D000596:Amino Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001930:Brain Injuries / Q000150:complications* / Q000188:drug therapy*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D012720:Severity of Illness Index; D013997:Time Factors; D014947:Wounds and Injuries
chemical_list: D000596:Amino Acids; D018697:Nootropic Agents; C006952:cerebrolysin